| Q71049501 | 29 Production and assay of antibodies to acetylcholine receptors |
| Q36601913 | A library of monoclonal antibodies to Torpedo cholinergic synaptosomes |
| Q43794971 | A murine cytomegalovirus-neutralizing monoclonal antibody exhibits autoreactivity and induces tissue damage in vivo. |
| Q70870998 | A new mechanism revealed for the action of antibodies on acetylcholine receptor function |
| Q70391866 | A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis |
| Q67726583 | Acetylcholine receptor-reactive antibodies in experimental autoimmune myasthenia gravis differing in disease-causing potential: Subsetting of serum antibodies by preparative isoelectric focusing |
| Q72664380 | Acetylcholine receptor: molecular dissection and monoclonal antibodies in the study of experimental myasthenia |
| Q44859084 | Adverse effects of myasthenia gravis on rat phrenic diaphragm contractile performance |
| Q73624853 | Age-related susceptibility to experimental autoimmune myasthenia gravis: immunological and electrophysiological aspects |
| Q41326666 | Aggressive surgical approach for drug-free remission from myasthenia gravis |
| Q37616547 | Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia |
| Q37384090 | Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis |
| Q46414744 | Antibody effector mechanisms in myasthenia gravis. The complement hypothesis |
| Q54247224 | Antigen presentation and T cell specificity repertoire in determining responsiveness to an epitope important in experimental autoimmune myasthenia gravis |
| Q33160247 | Autoimmune preganglionic sympathectomy induced by acetylcholinesterase antibodies |
| Q35021497 | Cell surface complement regulators moderate experimental myasthenia gravis pathology |
| Q39499669 | Cell-mediated immunity in neurologic disease |
| Q43789079 | Conjugation of acetylcholine receptor-protecting Fab fragments with polyethylene glycol results in a prolonged half-life in the circulation and reduced immunogenicity |
| Q38332160 | Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models. |
| Q47827280 | Electrophysiology of postsynaptic activation. |
| Q70330247 | Enzyma-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis |
| Q44457826 | Experimental autoimmune autonomic neuropathy |
| Q41517938 | Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment |
| Q67297389 | Experimental myasthenia: Lack of correlation between the autoantibody titer and the reduction of acetylcholine-controlled ionic channels measured at functioning endplates |
| Q73690086 | Functional association between nicotinic acetylcholine receptor and sarcomeric proteins via actin and desmin filaments |
| Q35738827 | Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs |
| Q37106516 | How myasthenia gravis alters the safety factor for neuromuscular transmission |
| Q53856594 | Immunology of myasthenia gravis. |
| Q38153563 | Immunopathologic events at the endplate in myasthenia gravis |
| Q39565382 | Immunopathology of acetylcholine receptors in myasthenia gravis |
| Q44131043 | In myasthenia gravis, clinical and immunological improvement post-thymectomy segregate with results of in vitro antibody secretion by immunocytes |
| Q71009433 | Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor |
| Q72092312 | Influence of Immunological Fine‐specificity on the Induction of Experimental Myasthenia Gravisa |
| Q77397615 | Inhibition of autoreactive antibody effects with antibody feedings: a pilot study |
| Q34724508 | Involvement of human muscle acetylcholine receptor alpha-subunit gene (CHRNA) in susceptibility to myasthenia gravis |
| Q40246548 | Islet cell antibodies in diabetes |
| Q44088405 | LF 15-0195 prevents from the development and inhibits the progression of rat experimental autoimmune myasthenia gravis |
| Q72570076 | Lack of cross-reactivity of a monoclonal antibody against the neurotransmitter site of Torpedo nicotinic acetylcholine receptor with muscle receptors from several sources |
| Q72390018 | Lipid-dependent recovery of alpha-bungarotoxin and monoclonal antibody binding to the purified alpha-subunit from Torpedo marmorata acetylcholine receptor. Enhancement by noncompetitive channel blockers |
| Q39740020 | Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection |
| Q38536614 | Monoclonal Antibodies in Urology |
| Q44824291 | Monoclonal Antibody to Acetylcholine Receptor: Cell Line Established from Thymus of Patient with Myasthenia Gravis |
| Q71397604 | Monoclonal antibodies directed against the neurotransmitter binding site of nicotinic acetylcholine receptor |
| Q70176476 | Monoclonal antibodies modify acetylcholine-induced ionic channel properties in cultured chick myoballs |
| Q52826144 | Monoclonal antibodies to cytoplasmic domains of the acetylcholine receptor |
| Q46428223 | Monoclonal autoantibodies to acetylcholine receptors: evidence for a dominant idiotype and requirement of complement for pathogenicity |
| Q95840969 | Muscle-Specific Kinase Myasthenia Gravis |
| Q29396951 | Myasthenia gravis |
| Q41687580 | Myasthenia gravis as a prototype autoimmune receptor disease |
| Q40487612 | Myasthenia gravis: An autoimmune response against the acetylcholine receptor |
| Q72753743 | Myasthenia gravis: In vitro immunoglobulin production with pokeweed mitogen challenge and B- and T-lymphocyte competence |
| Q26865228 | Myasthenia gravis: two case reports and review of the literature |
| Q44564715 | Myasthenia induced by monoclonal anti-acetylcholine receptor antibodies: Clinical and electrophysiological aspects |
| Q59071320 | Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients |
| Q70424026 | Neonatal myasthenia gravis in the infant of an asymptomatic thymectomized mother |
| Q33641955 | Neural autoantibody profile of primary achalasia |
| Q47606027 | Neuromuscular synapse electrophysiology in myasthenia gravis animal models |
| Q38070763 | Neuromuscular transmission failure in myasthenia gravis: decrement of safety factor and susceptibility of extraocular muscles |
| Q34604158 | Novel complement inhibitor limits severity of experimentally myasthenia gravis |
| Q33938477 | Passive transfer of autoimmune autonomic neuropathy to mice |
| Q67789403 | Postulates Defining Pathogenic Autoantibodies and T Cells |
| Q72152400 | Prevalence of ectopic thymic tissue in myasthenia gravis and its clinical significance |
| Q73539303 | Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor |
| Q57403182 | Rapid improvement of myasthenia gravis after plasma exchange |
| Q40325334 | Some properties and applications of monoclonal antibodies |
| Q67837035 | Subsetting of Acetylcholine Receptor-Reactive Antibodies by Preparative Isoelectric Focusing |
| Q34974981 | Targeting therapy to the neuromuscular junction: proof of concept. |
| Q70969834 | The Effect of Plasmapheresis on Post-Thymectomy Ocular Dysfunction |
| Q40112381 | The Human Thymic Microenvironment |
| Q70302012 | The Stability of Solubilized Mammalian Muscle Acetylcholine Receptors During Purification by Monoclonal Immunoadsorption |
| Q60521465 | The distribution of intracellular acetylcholine receptors and nuclei in developing avian fast-twitch muscle fibres during synapse elimination |
| Q43892653 | The immunological basis of inflammatory diseases |
| Q36719645 | The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies |
| Q36690423 | The main immunogenic region of the acetylcholine receptor. Structure and role in myasthenia gravis |
| Q79224123 | The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice |
| Q71364476 | [Heterogeneity of acetylcholine receptor antibodies in patients with myasthenia gravis] |
| Q49129904 | β-Endorphin and dynorphin control serum luteinizing hormone level in immature female rats |